UNICANCER
- Country
- France
- Type
- Beneficiary
- Grants received
- 13
Funding record
- 13 grants on record
- €16,631,157.83 awarded in total
- 2018–2026 years covered
This total adds up only the grants our sources publish. It is not the total funding this organisation has received.
Programmes
2 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations funded alongside this one on two or more projects. Sharing a single project does not count. Some projects have as many as 195 participants, and appearing on the same list once is not a working relationship.
- INSTITUT GUSTAVE ROUSSY
- ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE JULES BORDET
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
- EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
- GUSTAVE ROUSSY TRANSFERT
- INSTITUT CURIE
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
- MASARYKUV ONKOLOGICKY USTAV
Calls from this organisation
No published calls from this organisation.
Grants received
- Advancing Breast cancer Individualised Generative AI for Longitudinal Outcomes
- Cardio-Oncology Multidisciplinary Patient ASsistance Solution
- Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome
- OPTIMAL METHODS TO CHARACTERIZE ADC RESISTANCE IN SOLID TUMORS AND IDENTIFY CLINICALLY USEFUL BIOMARKERS
- Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients
- Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer
- INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL
- COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
- Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors
- Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
- PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification
- Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.
- International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
We collected this from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.